Harbour BioMed teams up with Lannacheng to advance next-generation cancer therapies

Harbour BioMed brings advanced antibody discovery platforms to the table

Senhwa Biosciences launches groundbreaking trial for HER2-positive tumours

CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development

Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial

Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis

Next Gen Diagnostics to spin off infection prevention unit

NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection

SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer

The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38

WuXi Biologics wins HERA 2025 Award for outstanding ESG disclosure

The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide

ENHERTU gains first-ever nod in China for metastatic breast cancer

The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy

Singlera Genomics partners with Pure Medical to bring early cancer detection to Europe

Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies

Govt cancels registration of popular cosmetic product over misleading claims

The cancellation underscores the regulator’s strict stance against misleading cosmetic claims

US House passes Bill reauthorizing FDA rare disease incentive program